GMED vs PEN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 23, 2026

GMED

37.4
AI Score
VS
PEN Wins

PEN

47.2
AI Score

Investment Advisor Scores

GMED

37score
Recommendation
SELL

PEN

47score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric GMED PEN Winner
Revenue 1.55B 764.80M GMED
Net Income 275.87M 67.39M GMED
Net Margin 17.8% 8.8% GMED
Operating Income 332.82M 79.27M GMED
ROE 5.8% 4.4% GMED
ROA 5.0% 3.4% GMED
Total Assets 5.49B 1.97B GMED
Cash 507.75M 205.27M GMED
Current Ratio 4.62 5.75 PEN
Free Cash Flow 339.32M 105.84M GMED

Relative Price Performance (Last 90 Days)

GMED 1M: +9.7% · 3M: +4.1% PEN 1M: +1.7% · 3M: +1.7%

Current Technical Phase

GMED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 63

RSI (14): 63.3 · Price: $81.47

PEN

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 68

RSI (14): 67.7 · Price: $325.08

Fundamentals Snapshot

Metric GMED PEN
Market Cap — —
Forward P/E 15.2 53.0
Trailing P/E 20.2 79.5
Revenue (TTM) — —
Revenue Growth 0.1% 0.1%
Gross Margin 0.7% 0.7%
Operating Margin 0.2% 0.1%
EPS 3.90 4.07
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, PEN is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.